Navigation Links
Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
Date:10/29/2009

ansdermal system) CII

October 30, 2009; 3:00 pm to 5:30 pm ET / 9:00 am to 11:30 am HT

Pharmacokinetics of Methylphenidate Transdermal System and Osmotic-Release Oral System Methylphenidate in Children and Adolescents With ADHD

Poster Presentation # 4.52

October 30, 2009; 3:00 pm to 5:30 pm ET / 9:00 am to 11:30 am HT

Pharmacokinetic Predictors of Abuse-Related Liking With Transdermal and Subcutaneous Methylphenidate

Poster Presentation # 4.54

October 30, 2009; 3:00 pm to 5:30 pm ET / 9:00 am to 11:30 am HT

Evaluation of the Tolerability and Effectiveness of the Methylphenidate Transdermal System Over 6 Months in Adolescents With ADHD

Poster Presentation # 4.55

Additional information about INTUNIV and Full Prescribing Information are available at http://www.intuniv.com.

Additional information about Vyvanse and Full Prescribing Information, including the Medication Guide, are available at http://www.vyvanse.com.

Additional information about Daytrana and Full Prescribing Information, including the Medication Guide, are available at http://www.daytrana.com.

INTUNIV IMPORTANT SAFETY INFORMATION

INTUNIV is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17. Efficacy was established in two controlled clinical trials (8 and 9 weeks in duration). The physician electing to use INTUNIV for extended periods should periodically reevaluate its long-term usefulness for the individual patient.

INTUNIV should not be used in patients with a history of hypersensitivity to gua
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
2. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
3. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
4. Veriscrip and DAMMAD Team Up to Combat Prescription Drug Abuse in New Hampshire
5. New Hampshire Rx Card Launching Statewide
6. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
7. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
8. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
9. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 21, 2014  Alere Inc. (NYSE: ... diagnostic tests, has appointed Juliet Cunningham as ... Cunningham will be responsible for driving communications with the ... on a series of changes to increase shareholder value, ... to investors," said Namal Nawana, Chief Executive Officer. "We ...
(Date:11/21/2014)... 2014 In September 2014, the staff at ... a new product development plan that started with the ... lab coat , aptly named "Vera G.," after ... the world. The new women,s designer lab coat is ... sleek envelope collar, vertical princess and high waist seaming, ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
(Date:11/22/2014)... November 22, 2014 Setria® Glutathione ... (TGA) approved it for use “as a therapeutically ... listed within the Therapeutic Goods (Listing) Notice 2014 ... Kyowa Hakko’s Setria® Glutathione will be exclusivity distributed ... that sources and imports fine chemicals to Australian ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Nocturia ... as the complaint that the individual has to ... voiding. The report “Nocturia – Pipeline Review, H2 ... for Nocturia, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:11/22/2014)... 22, 2014 (HealthDay News) -- The wide variety and ... a threat for people with food allergies, an expert ... so many types of food allergies that it can ... holidays," Dr. Guha Krishnaswamy, director of allergy and clinical ... a hospital news release. "If you know you ...
(Date:11/22/2014)... 2014 Hastings and Hastings, a discount ... announces providing clients with the option of leaving an ... a flexible, intuitive and easy to navigate website that ... to Google + allows clients to research the Hastings ... more informed decision when retaining an attorney. Those who ...
(Date:11/22/2014)... Boulder, CO (PRWEB) November 22, 2014 ... on growth equity investments in the consumer brand ... LLC. The investment will be used to help ... new product pipeline rollout, particularly its proprietary apparel ... Suslow will join BackJoy’s Board of Directors. , ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3
... the sleep disturbances, study finds , WEDNESDAY, Dec. 2 (HealthDay ... increase the risk of sleep apnea, say U.S. researchers. , ... damages the brain and can cause immediate and dangerous problems ... the Johns Hopkins School of Medicine in Baltimore, said in ...
... say , WEDNESDAY, Dec. 2 (HealthDay News) -- New research ... in the lives of people with Fabry disease, a rare ... The progressive disease, linked to the lack of an enzyme ... fatal because it boosts the risk for a stroke, heart ...
... 2 Huntington Memorial Hospital,s stroke program has received ... designating the hospital a primary stroke center. This ... center" hospitals throughout Los Angeles County. , ... more important, a wonderful benefit for Pasadena and its ...
... SAN FRANCISCO, Dec. 2 In the wake of the ... plastics chemical linked to birth defects and breast cancer, Congress ... House and Senate are considering bills to ban bisphenol A, ... Sen. Dianne Feinstein of California and Rep. Edward Markey of ...
... , ... , WASHINGTON, Dec. 2 The membership of the National Quality ... and reappointed four current Board members. The new Board members represent ... suppliers, and public and community healthcare. , The newly elected ...
... , NEW YORK, Dec. 2 Care ... Advanced Illness Coordinated Care (AICC) , has been shown to reduce ... the quality of life for seniors and their family caregivers without ... published in American Journal of Managed Care (November 2009). ...
Cached Medicine News:Health News:Ecstasy Users at Higher Risk of Sleep Apnea 2Health News:Huntington Hospital Earns Designation as Primary Stroke Center 2Health News:Pre-Polluted Babies: Congress Must Act to Protect Infants, Moms from Toxic Plastics Chemical BPA 2Health News:National Quality Forum Members Elect Nine Directors to Board 2Health News:National Quality Forum Members Elect Nine Directors to Board 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 2Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 4
... The challenge for Carl Zeiss was ... on the eye and for preoperative ... result of this development work is ... revolutionizing all previous techniques and setting ...
Ahmed Glaucoma Valve (small size) with Pars Plana Clip ....
Ahmed Glaucoma Valve....
... biocompatibility is established. Provides a robust and ... correct positioning on the globe. Pressure Ridge ... when covered by Tenons tissue, acts as ... hypotony. The range of implants allows the ...
Medicine Products: